If drugmakers have their way, the federal government likely ends up spending $100 billion of taxpayer funds to bail out rural hospitals.

This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of 340B drugs without the perverse incentives perpetuated by the current ...

The American Society of Health-System Pharmacists is urging lawmakers to protect the 340B Drug Pricing Program, warning that changes to the discount model could destabilize safety-net hospitals. In an ...

Discount drug program requires drug companies to sell deeply discounted drugs to hospitals that serve high numbers of ...

AHA writes to express our strong support for this vital program that allows eligible hospitals to maintain, improve and expand access to essential services and medications for the patients and ...

Following Eli Lilly and Johnson & Johnson, Sanofi is aiming to change how it participates in the 340B program, a federal drug pricing program created in 1992, The Wall Street Journal reported Nov. 22.

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

Katherine Denney, Alissa Fleming, Gregory Fliszar Ph.D. In the fall of 2024, several pharmaceutical companies reacted to HRSA's decision to prevent them from implementing a rebate model for their ...

Inaccurate information, pushbacks and undue limitations imposed by pharmaceutical manufacturers pose a threat to the 340B ...

An obscure, supposedly free federal program is blowing a hole in state budgets – by depriving state governments of billions in corporate tax revenue and inflating costs for their public employee ...